Thimerosal Characterization In Children Should Be Research Focus - Zoon
Characterization of thimerosal's effects in vaccinated children should constitute a significant portion of immediate research, balanced with research into new types of vaccine preservatives, FDA Center for Biologics Evaluation & Research Director Kathyrn Zoon, PhD, said at the National Vaccine Advisory Committee-sponsored workshop on thimerosal in vaccines Aug. 12.
You may also be interested in...
Concrete plans and a realistic timeframe for vaccine manufacturers to eliminate or reduce thimerosal from their products will be discussed at a public workshop between manufacturers, Public Health Service agencies and the American Academy of Pediatrics.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials